Ugur Sahin
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ugur Sahin has a total of 131 co-authors. Here are the top co-authors by number of shared publications:
- Muhit Özcan
Ankara University School of Medicine, Ankara, Turkey
11 shared publications - Önder Arslan
Department of Hematology, School of Medicine, Ankara University, Ankara, Türkiye
9 shared publications - Ayla Gökmen
Medicana International Ankara Hospital, Clinic of Hematology, Ankara, Türkiye
8 shared publications - Gunhan Gurman
Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
8 shared publications - Taner Demirer
Department of Hematology, Ankara University Faculty of Medicine, Ankara, Turkey
8 shared publications Kadri Altundag
Hacettepe University Cancer Institute, Department of Medical Oncology, Ankara, Turkey, Ankara, Turkey
7 shared publications
Latest Publications
- Open Access
- 2 June 2026
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 116-130
Allogeneic Hematopoietic Cell Transplantation for Relapsed/ Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience
AlloHCT remains a curative option for R/R Hodgkin lymphoma despite advances with BV and CPIs. This study evaluates its role and outcomes in this challenging patient population. This retrospective oligocentric analysis involved 70 patients with R/R classical HL who underwent alloHCT. Patients were split into two treatment cohorts: era1 (2004-2010), 16 patients, and era2 (2011-2021), 54 patients. Among the cohort, sixty-three patients had previously received an autologous stem cell transplant. Forty patients were administered only (n=29) BV or BV preceding CPI (n=11) before alloHCT. A median follow-up of 64 months (40.7-87.3) revealed a 100-day non-relapse mortality (NRM) rate of 26%, with the 3-year overall survival (OS) and progression-free survival (PFS) reported as 39% and 28%, respectively. AlloHCT using haplotype-matched donors was linked to better OS and PFS. Post-transplant cyclophosphamide (post-tx CY) as a prophylactic approach for graft versus host disease (GVHD) significantly improved OS and PFS. A complete response (CR) during the post-transplant phase significantly improved OS and PFS. Indeed, better OS, PFS, and a reduced rate of NRM were observed in the pre/post-alloHCT BV and CPI group, although we could not demonstrate statistical significance. The survival (OS, PFS) curves and NRM rates were similar for both eras. AlloHCT is a potentially practical therapeutic approach in responding to R/R HL patients.
- 2 June 2026
- Published by Galenos Yayinevi in Turkish Journal of Hematology
- Vol. 43 (2) , 116-130
Open AccessAllogeneic Hematopoietic Cell Transplantation for Relapsed/ Refractory Hodgkin Lymphoma: A Multicenter Real-World Experience
AlloHCT remains a curative option for R/R Hodgkin lymphoma despite advances with BV and CPIs. This study evaluates its role and outcomes in this challenging patient population. This retrospective oligocentric analysis involved 70 patients with R/R classical HL who underwent alloHCT. Patients were split into two treatment cohorts: era1 (2004-2010), 16 patients, and era2 (2011-2021), 54 patients. Among the cohort, sixty-three patients had previously received an autologous stem cell transplant. Forty patients were administered only (n=29) BV or BV preceding CPI (n=11) before alloHCT. A median follow-up of 64 months (40.7-87.3) revealed a 100-day non-relapse mortality (NRM) rate of 26%, with the 3-year overall survival (OS) and progression-free survival (PFS) reported as 39% and 28%, respectively. AlloHCT using haplotype-matched donors was linked to better OS and PFS. Post-transplant cyclophosphamide (post-tx CY) as a prophylactic approach for graft versus host disease (GVHD) significantly improved OS and PFS. A complete response (CR) during the post-transplant phase significantly improved OS and PFS. Indeed, better OS, PFS, and a reduced rate of NRM were observed in the pre/post-alloHCT BV and CPI group, although we could not demonstrate statistical significance. The survival (OS, PFS) curves and NRM rates were similar for both eras. AlloHCT is a potentially practical therapeutic approach in responding to R/R HL patients.
- 6 December 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (4) , 468.e1-468.e14
Cladribine as an Alternative to Fludarabine in Melphalan and Total Body Irradiation-Based Reduced Intensity Conditioning
- 6 December 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (4) , 468.e1-468.e14
Cladribine as an Alternative to Fludarabine in Melphalan and Total Body Irradiation-Based Reduced Intensity Conditioning
- 1 October 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (1) , 102-103
Comment on Factors Affecting Haploidentical Transplant Outcomes with Posttransplant Cyclophosphamide Plus ATG
- 1 October 2025
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 32 (1) , 102-103
Comment on Factors Affecting Haploidentical Transplant Outcomes with Posttransplant Cyclophosphamide Plus ATG
- 28 April 2025
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 9 (1) , 14-20
AL Amiloidozda Otolog Kök Hücre Nakli ile Daratumumab Tabanlı İndüksiyon ve İdame Tedavilerinin Sağkalıma Etkisi
- 28 April 2025
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 9 (1) , 14-20
AL Amiloidozda Otolog Kök Hücre Nakli ile Daratumumab Tabanlı İndüksiyon ve İdame Tedavilerinin Sağkalıma Etkisi
- 3 December 2024
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 8 (3) , 92-97
Relaps Nodüler Lenfosit Predominant Hodgkin Lenfomada Kurtarma Tedavisi Sonrası Otolog Kök Hücre Nakli Sonuçları
- 3 December 2024
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 8 (3) , 92-97
Relaps Nodüler Lenfosit Predominant Hodgkin Lenfomada Kurtarma Tedavisi Sonrası Otolog Kök Hücre Nakli Sonuçları
- 3 December 2024
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 8 (3) , 81-85
Akut Miyeloid Lösemide BCL-2 İnhibitörü Venetoklaks: Yaşlı Hastada Gerçek Yaşam Deneyimi
- 3 December 2024
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 8 (3) , 81-85
Akut Miyeloid Lösemide BCL-2 İnhibitörü Venetoklaks: Yaşlı Hastada Gerçek Yaşam Deneyimi
- 22 August 2023
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 7 (2) , 51-56
Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Aseptik Nekroz Gelişen Olgularda Vitamin D Reseptör Gen Polimorfizmi
- 22 August 2023
- Published by Bilimsel Tip Publishing House in LLM Dergi
- Vol. 7 (2) , 51-56
Allojeneik Hematopoetik Kök Hücre Nakli Sonrası Aseptik Nekroz Gelişen Olgularda Vitamin D Reseptör Gen Polimorfizmi
- 28 July 2023
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 38 (6) , 685-693
Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation
Background: Adequate stem cell collection is essential for successful stem cell transplantation. Heparin enhances stem cell mobilization by competing with heparin sulfate proteoglycans. Heparin is also used as an anticoagulant before leukapheresis. Here, we evaluated the effects of heparin on stem cell mobilization in patients who underwent autologous stem cell transplantation (ASCT). Methods: We evaluated patients who underwent ASCT. Patients were divided into two groups: those who received heparin plus citrate (heparinized patients) and those who received citrate only (nonheparinized patients) for anticoagulation. Univariate and multivariate analyses were also performed. The collection efficiency 2 (CE2) for CD34+ cells was calculated and compared between heparinized and nonheparinized patients. Results: This study included 1017 patients. There were 478 (47%) heparinized and 539 (53%) nonheparinized patients. The number of collected CD34+ cells was significantly higher in heparinized patients ( P < .00001). The multivariate analyses showed that using heparin was an independent positive factor for collected CD34+ cells (adj‐ R 2 = 0.744; F = 369.331, P < .00001). CE2 was significantly higher in heparinized patients than in nonheparinized patients (66.8% vs 52.1%; P < .00001). The rate of collecting at least 2 × 10 6 /kg CD34+ cells was 3.3 times higher for heparinized patients in poor mobilizers ( P < .00001). Heparinized patients had significantly higher total nucleated and mononuclear cell counts ( P < .00001 and <.00001, respectively). Conclusion: Heparin enhances stem cell collection and increases CE2. The use of heparin may reduce the need for other strategies to increase stem cell mobilization.
- 28 July 2023
- Published by Wiley in Journal of Clinical Apheresis
- Vol. 38 (6) , 685-693
Stem cell mobilizating effect of heparin in patients undergoing autologous stem cell transplantation
Background: Adequate stem cell collection is essential for successful stem cell transplantation. Heparin enhances stem cell mobilization by competing with heparin sulfate proteoglycans. Heparin is also used as an anticoagulant before leukapheresis. Here, we evaluated the effects of heparin on stem cell mobilization in patients who underwent autologous stem cell transplantation (ASCT). Methods: We evaluated patients who underwent ASCT. Patients were divided into two groups: those who received heparin plus citrate (heparinized patients) and those who received citrate only (nonheparinized patients) for anticoagulation. Univariate and multivariate analyses were also performed. The collection efficiency 2 (CE2) for CD34+ cells was calculated and compared between heparinized and nonheparinized patients. Results: This study included 1017 patients. There were 478 (47%) heparinized and 539 (53%) nonheparinized patients. The number of collected CD34+ cells was significantly higher in heparinized patients ( P < .00001). The multivariate analyses showed that using heparin was an independent positive factor for collected CD34+ cells (adj‐ R 2 = 0.744; F = 369.331, P < .00001). CE2 was significantly higher in heparinized patients than in nonheparinized patients (66.8% vs 52.1%; P < .00001). The rate of collecting at least 2 × 10 6 /kg CD34+ cells was 3.3 times higher for heparinized patients in poor mobilizers ( P < .00001). Heparinized patients had significantly higher total nucleated and mononuclear cell counts ( P < .00001 and <.00001, respectively). Conclusion: Heparin enhances stem cell collection and increases CE2. The use of heparin may reduce the need for other strategies to increase stem cell mobilization.
- Open Access
- 25 October 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (6) , 1718-1724
Oxidative stress indicators during the course of acute graft versus host disease
Aim: This prospective study aimed to observe the changes in oxidative stress indicators, including total anti-oxidant status (TAS), total oxidant status (TOS), paraoxanase-1 (PON1), total thiol (TT), native thiol (NT), disulphide (DS) and nitric oxide (NO) levels from sequential blood samples obtained during a de-novo episode of acute graft versus host disease (aGvHD) and evaluate their association with disease severity and the risk of steroid resistant disease. Material and Method: Sequential patients who underwent an allogeneic stem cell transplantation (ASCT) in our unit and subsequently developed a de-novo episode of aGvHD between January 2022 and May 2022 were included in case they gave informed consent. All patients were started high dose (2 mg/kg/day) methylprednisolone as institutional standard first-line treatment of aGvHD as soon as the clinical diagnosis is evident. All episodes were confirmed simultaneously with gastrointestinal (GI) endoscopy and/or skin biopsies. TAS, TOS, PON1, TT, NT, DS and NO were studied from blood samples collected on days 0, +3 and +7 of steroid treatment. Demographic characteristics, diagnoses, donor type, GvHD prophylaxis, stage and grade of aGvHD, performance status (PS), the presence of cytomegalovirus (CMV) reactivation and response to steroid therapy were also noted. Results: A total of 15 cases was included. The median age was 49 (23-77). Males constituted 60.0% (n=9). The most frequent diagnosis and donor type were acute leukemia (53.3%, n=8) and matched related donor (46.7%, n=7), respectively. High grade aGvHD with Glucksberg grading and International Bone Marrow Transplant Registry severity index (IBMTR-SI) included 53,3% (n=8) and 86.7% (n=10) of cases, respectively. Non-responders (20.0%, n=3) significantly had advanced stage GI involvement, higher grade of aGvHD with Glucksberg grading and IBMTR-SI, and lower PS (p=0.005, p=0.04, p=0.006, and p=0.02, respectively). The changes in TAS, TOS, PON1, TT, NT, DS and NO levels on days 0, +3 and +7 of steroid treatment were not significant. Median PON1 levels on days 0, +3 and +7 of steroid treatment were significantly lower among non-responders (p
- 25 October 2022
- Published by Journal of Health Sciences and Medicine in Journal of Health Sciences and Medicine
- Vol. 5 (6) , 1718-1724
Open AccessOxidative stress indicators during the course of acute graft versus host disease
Aim: This prospective study aimed to observe the changes in oxidative stress indicators, including total anti-oxidant status (TAS), total oxidant status (TOS), paraoxanase-1 (PON1), total thiol (TT), native thiol (NT), disulphide (DS) and nitric oxide (NO) levels from sequential blood samples obtained during a de-novo episode of acute graft versus host disease (aGvHD) and evaluate their association with disease severity and the risk of steroid resistant disease. Material and Method: Sequential patients who underwent an allogeneic stem cell transplantation (ASCT) in our unit and subsequently developed a de-novo episode of aGvHD between January 2022 and May 2022 were included in case they gave informed consent. All patients were started high dose (2 mg/kg/day) methylprednisolone as institutional standard first-line treatment of aGvHD as soon as the clinical diagnosis is evident. All episodes were confirmed simultaneously with gastrointestinal (GI) endoscopy and/or skin biopsies. TAS, TOS, PON1, TT, NT, DS and NO were studied from blood samples collected on days 0, +3 and +7 of steroid treatment. Demographic characteristics, diagnoses, donor type, GvHD prophylaxis, stage and grade of aGvHD, performance status (PS), the presence of cytomegalovirus (CMV) reactivation and response to steroid therapy were also noted. Results: A total of 15 cases was included. The median age was 49 (23-77). Males constituted 60.0% (n=9). The most frequent diagnosis and donor type were acute leukemia (53.3%, n=8) and matched related donor (46.7%, n=7), respectively. High grade aGvHD with Glucksberg grading and International Bone Marrow Transplant Registry severity index (IBMTR-SI) included 53,3% (n=8) and 86.7% (n=10) of cases, respectively. Non-responders (20.0%, n=3) significantly had advanced stage GI involvement, higher grade of aGvHD with Glucksberg grading and IBMTR-SI, and lower PS (p=0.005, p=0.04, p=0.006, and p=0.02, respectively). The changes in TAS, TOS, PON1, TT, NT, DS and NO levels on days 0, +3 and +7 of steroid treatment were not significant. Median PON1 levels on days 0, +3 and +7 of steroid treatment were significantly lower among non-responders (p